Abstract
The identification and validation of biomarkers for preclinical patients with mild cognitive impairment (MCI) at-risk for Alzheimer’s disease (AD) development is increasingly important. We used the cytofluorimetric analysis of unfolded p53 to determine the prognostic ability of the protein as predictive signature from MCI to AD in a longitudinal study of a population of presymptomatic patients with the clinical diagnosis of MCI.
Venous blood samples from 24 healthy subjects, 28 MCI and 15 AD were analyzed with the cytofluorimetric method for unfolded p53 protein detection. Twenty-four MCI patients had clinical follow-up subsequent to the analysis for unfolded p53. Elevated levels of the conformationally altered protein were able to discriminate both MCI and AD patients comparing with healthy subjects. Longitudinal follow-up revealed that 7/24 MCI patients progressed to AD. All converters (100%) were predicted by elevated levels of unfolded p53, with a positive predictive value of 87.5%.
These data support and extend our previous observation that the cytofluorimetric approach for unfolded p53 protein was able to discriminate AD patients from healthy subjects and to predict the progression from MCI to AD in presymptomatic patients before clinical diagnosis for AD was evident.
Keywords: Alzheimer’s disease (AD), blood biomarker, flow cytometry, mild cognitive impairment (MCI), unfolded p53, positive predictive value, Molecular Genetic, neuropsychological battery
Current Alzheimer Research
Title:Searching for Predictive Blood Biomarkers: Misfolded p53 In Mild Cognitive Impairment
Volume: 9 Issue: 10
Author(s): Serena Stanga, Cristina Lanni, Elena Sinforiani, Giuliano Mazzini and Marco Racchi
Affiliation:
Keywords: Alzheimer’s disease (AD), blood biomarker, flow cytometry, mild cognitive impairment (MCI), unfolded p53, positive predictive value, Molecular Genetic, neuropsychological battery
Abstract: The identification and validation of biomarkers for preclinical patients with mild cognitive impairment (MCI) at-risk for Alzheimer’s disease (AD) development is increasingly important. We used the cytofluorimetric analysis of unfolded p53 to determine the prognostic ability of the protein as predictive signature from MCI to AD in a longitudinal study of a population of presymptomatic patients with the clinical diagnosis of MCI.
Venous blood samples from 24 healthy subjects, 28 MCI and 15 AD were analyzed with the cytofluorimetric method for unfolded p53 protein detection. Twenty-four MCI patients had clinical follow-up subsequent to the analysis for unfolded p53. Elevated levels of the conformationally altered protein were able to discriminate both MCI and AD patients comparing with healthy subjects. Longitudinal follow-up revealed that 7/24 MCI patients progressed to AD. All converters (100%) were predicted by elevated levels of unfolded p53, with a positive predictive value of 87.5%.
These data support and extend our previous observation that the cytofluorimetric approach for unfolded p53 protein was able to discriminate AD patients from healthy subjects and to predict the progression from MCI to AD in presymptomatic patients before clinical diagnosis for AD was evident.
Export Options
About this article
Cite this article as:
Stanga Serena, Lanni Cristina, Sinforiani Elena, Mazzini Giuliano and Racchi Marco, Searching for Predictive Blood Biomarkers: Misfolded p53 In Mild Cognitive Impairment, Current Alzheimer Research 2012; 9 (10) . https://dx.doi.org/10.2174/156720512804142886
DOI https://dx.doi.org/10.2174/156720512804142886 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets A Comprehensive Review of Alzheimer’s Association with Related Proteins: Pathological Role and Therapeutic Significance
Current Neuropharmacology Neuroprotection for Amyotrophic Lateral Sclerosis: Role of Stem Cells, Growth Factors, and Gene Therapy
Central Nervous System Agents in Medicinal Chemistry Bridging Over the Troubled Heterogeneity of SPG-Related Pathologies: Mechanisms Unite What Genetics Divide
Current Molecular Medicine Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
Current Drug Metabolism Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry Traumatic Brain Injury: Preclinical Imaging Diagnostic(s) and Therapeutic Approaches
Current Pharmaceutical Design RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine
Current Alzheimer Research Editorial (Thematic Issue: Emerging Biomarkers for Drug Development in Amyotrophic Lateral Sclerosis)
Current Medicinal Chemistry Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience